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Summary: The polymerase chain reaction with prior reverse transcription of RNA into cDNA was applied
to hepatitis C virus RNA detection in human serum samples of different origin. In order to eliminate false
negative results, the following steps were optimized: RNA extraction, reverse transcription, and oligonucleotide
primer selection.
We compared different RNA extraction methods using guanidinium salt/detergent and proteinase K digestion/
phenol extraction, and tested virus particle enrichment with polyethylene glycol precipitation and ultracen-
trifugation. RNA extraction with guanidinium salt/detergent was the most efficient method.
Ultracentrifugation of single samples did not improve hepatitis C virus RNA detection. Polyethylene glycol
precipitation performed poorly.
Recombinant thermostable reverse transcriptase produced cDNA from fewer samples than did Moloney
murine leukaemia virus reverse transcriptase.
Nested oligonucleotide primers from the 5'-terminal non-coding region of the hepatitis C virus genome
amplified cDNA from more samples than did primers from the coding regions. Thirty six anti-hepatitis C
virus antibody positive samples were tested; nested primers (nucleotides 6 to 327 and 15 to 288) yielded 21
amplificates, whereas primers from the coding region produced 16 amplificates (nucleotides 4684 — 5276) and
5 amplificates (nucleotides 5166 — 5270), respectively.
The most efficient combination of steps was RNA extraction with guanidinium salt solution, reverse tran-
scription with Moloney murine leukaemia virus reverse transcriptase and nested polymerase chain reaction
primed with primers from the 5'-terminal non-coding region of the hepatitis C virus genome. Other combi-
nations produced more false negative results.
Three different groups of anti-hepatitis C virus antibody positive individuals had markedly different viraemia
patterns: Hepatitis C virus RNA was detected in the sera of only 10% of anti-hepatitis C virus antibody
positive blood donors, but in 90% of anti-hepatitis C virus antibody positive patients with clinically manifest
hepatitis C, and 90% of anti-hepatitis C virus antibody positive haemophiliacs who had received plasma
products in the past which had not been virus-inactivated. No hepatitis C virus RNA could be detected in
the sera of 450 anti-hepatitis C virus antibody negative blood donors with elevated serum alanine aminotrans-
ferase catalytic concentrations.
Introduction f , . r uu . . „ . ffor the major part of hepatitis non-A, non-B infec-
The hepatitis C virus, a single stranded RNA virus tions (1 — 5). Its nucleic acid sequence was determined
with some structural relations to the flavivirus family, from cDNA clones derived from the nucleic acid
has been identified as the infectious agent responsible extracts of the plasma of an experimentally infected
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chimpanzee (1). The natural modes of hepatitis C
virus transmission are not yet completely understood
(3, 6). Since the introduction of the hepatitis B surface
antigen assay to blood donor screening in 1972, how-
ever, it has been known that blood transfusions and
parenterally administered human blood products (e. g.
coagulation factors, or fresh frozen plasma) constitute
a major route of "hepatitis non-A, non-B" transmis-
sion (7).
The nucleic acid sequences of the first hepatitis C
virus cDNA clones provided the basis for the con-
struction of recombinant peptides representing puta-
tive hepatitis C virus proteins (4, 8). Cloned hepatitis
C virus peptides were employed in anti-hepatitis C
virus enzyme immunoassays. Since 1989, such enzyme
immunoassays have identified many clinical cases of
"hepatitis non-A, non-B" as hepatitis C virus infec-
tions (4, 9, 10, 11). Anti-hepatitis C virus antibody
screening of blood using these enzyme immunoassays,
helped to identify and sort out apparently healthy
blood donors with anti-hepatitis C virus antibodies
who otherwise might have transmitted the virus (11).
At present, hepatitis C virus cannot be detected by
cell culture techniques. Neither can the virus be dem-
onstrated with certainty by electron microscopy. This
may be due to the comparatively low particle numbers
of the virus (100 — 1000 χ 103/1) in viraemic samples
(12, 13). For the same reason, other methods for the
detection of specific nucleic acid sequences, such as
dot blot hybridization (14) or luminescence-labelled
direct hybridization (15) are not applicable to hepa-
titis C virus detection.
The polymerase chain reaction with prior reverse tran-
scription of viral RNA into cDNA is at present the
only method applicable to hepatitis C virus detection.
The general potential of this method became evident
very soon after the discovery of the hepatitis C virus,
but rather different results were obtained with differ-
ent primers and different RNA extraction methods
(12, 16 — 23). Such divergent results of hepatitis C
virus RNA detection are in part due to the fact that
the various isolates of hepatitis C virus exhibit rather
low RNA sequence homologies for the major part of
the genome (1, 8, 24-29, 45). However, the 5'-ter-
minal non-coding region is highly conserved (21, 30,
31, 32), thus providing a good target for the poly-
merase chain reaction. We compared oligonucleotide
primers targeted at different sections of the genome,
including the highly conserved 5'-terminal non-coding
region (12, 17, 20).
The method was optimized for the monitoring of
patients and blood donors.
Materials and Methods
Sera
Five hundred thirty three (533) sera were assayed. They were
obtained from
1. Blood donors (n = 486)
1.1. Anti-hepatitis C virus antibody negative blood donors
with elevated serum alanine aminotransferase (above 25
U/l) (n = 450),
1.2. Apparently healthy anti-hepatitis C virus antibody posi-
tive, anti-HBc negative blood donors with serum alanine
aminotransferase below 25 U/l (n = 36),
2. Haemophiliacs (n = 22)
2.1. Anti-hepatitis C virus antibody positive haemophiliacs
who had received multiple doses of plasma-derived clot-
ting factors before the introduction of plasma inactivation
procedures (n = 19),
2.2. Anti-hepatitis C virus antibody negative juvenile haemo-
philiacs who had exclusively received virus inactivated
human plasma products (n = 3),
3. Anti-hepatitis C virus antibody positive patients with hep-
atitis non-A, non-B (n = 30),
3.1. Patients with acute hepatitis non-A, non-B (n = 6),
3.2. Patients with chronic hepatitis non A, non-B (22),
3.3. Cardiac surgery patients whose anti-hepatitis C virus an-
tibodies had been discovered by pre-operative serological
screening (n = 2).
The sera were stored at -20 °C.
RNA preparation
The whole extraction process was performed in 1.5 ml plastic
tubes (Eppendorf, Hamburg), and centrifugations were per-
formed at 10500g and 6 °C, unless stated otherwise.
Guanidinium salt extraction
Serum (200 μΐ) was mixed with 600 μΐ 4 mol/1 guanidinium
isothiocyanate, 25 mmol/1 sodium citrate pH 7.0, 5 g/1 N-lau-
roylsarcosine, 0.1 mol/1 mercaptoethanol in 1.5 ml tubes at
room temperature by brief vortexing. Phenol equilibrated with
1 mol/1 Tris-Cl, pH 7.5 (600 μΐ) was added and the tubes were
vortexed. A solution of baker's yeast RNA (type III, Sigma,
Taufkirchen) (1.2 g/l, 2 μΐ) was added and mixed, followed by
100 μΐ chloroform. The tubes were briefly vortexed again, placed
on ice for 15 minutes and centrifuged for 15 minutes. The upper
aqueous phases (ca 750 μΐ) were transferred to new tubes and
extracted with an equal volume of chloroform. The interphases,
containing proteinaceous material, were completely left behind.
The mixtures were again centrifuged as before, and the aqueous
layers without interphases were transferred to new tubes and
mixed with at least an equal volume (or up to two volumes) of
ice cold isopropanol. The tubes were left overnight at —20 °C,
then centrifuged for 20 minutes. The supernatants were care-
fully poured off.
The pellets were washed with 200 μΐ of aqueous ethanol, volume
fraction 0.7. After decantation, the tubes were left open for 60
min at 40 °C in order to dry out before the pellets were redis-
solved in 10 μΐ aqua ad iniectabilia (RNase free). The solutions
were frozen at —20 °C for storage or used directly for reverse
transcription (modified according to I.e. (12) and (33).
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Proteinase K digestion
Serum (50 μΐ) was diluted with 1 50 μΐ aqua ad iniectabilia and
200 μΐ lysis buffer, containing 0.2 mol/1 Tris-Cl pH 7.5, 25
mmol/1 EDTA, 0.3 mol/1 NaCl and 20 g/l SDS. A stock solution
(2 μΐ) containing 20 g/1 Proteinase Κ (Merck, Darmstadt) was
added, and the mixtures were incubated for 90 minutes at 37 °C,
followed by two extractions, each with 400 μΐ phenol (equili-
brated with 1 mol/1 Tris-Cl, pH 7.5)/chloroform/isoamyl alco-
hol (25/24/1 by vol.), then one extraction with 300 μΐ chloro-
form. After each extraction the aqueous phases were transferred
to new tubes, and the interphases, containing proteinaceous
material, were completely left behind. To the final aqueous
phases 1 μΐ of a stock solution of glycogen (from mussels, 20
g/1, Boehringer, Mannheim) and then 900 μΐ of ice cold ethanol
were added, and the tubes were left overnight at —20 °C. The
precipitates were collected by centrifugation for 20 minutes.
The pellets were vortexed in 200 μΐ pure ethanol, re-centrifuged
for 20 minutes and dried at 40 °C after decantation of the
superaatants. The dried pellets were dissolved in 10 μΐ aqua ad
iniectabilia and either used directly for reverse transcription or
stored at -20 °C (modified ace. to I.e. (19)).
Polyethylene glycol precipitation
Serum (500 μΐ) diluted with 500 μΐ aqua ad iniectabilia, and
500 μΐ 300 g/1 polyethylene glycol, average Mr 8000 (Serva,
Heidelberg), in 0.1 mol/1 NaCl were added. After brief vortex-
ing, the tubes were placed on ice for 60 minutes before centrif-
ugation for 15 minutes. The superaatants were completely re-
moved by aspiration, and the pellets dissolved in 300 μΐ Tris/
EDTA buffer (10 mmol/1 Tris-Cl pH 7.0, 1 mmol/1 EDTA).
Following the addition of 40 μΐ 100 g/1 SDS, the mixtures were
extracted with 300 μΐ phenol (equilibrated with 1 mol/1 Tris-Cl
pH 7.5), then centrifuged for 10 min. The aqueous phases were
transferred to new tubes and extracted with 300 μΐ chloroform.
After 5 minutes centrifugation, the aqueous phases were trans-
ferred to tubes prefilled with 30 μΐ 3 mol/1 sodium acetate, pH
5.0. Glycogen stock solution (from mussels, 20 g/1, Boehringer,
Mannheim) (1 μΐ) was added and the tubes were vortexed. Ice
cold ethanol (1 ml) was added, the tubes were briefly vortexed
again and left overnight at —65 °C. After centrifugation for 20
minutes, the superaatants were completely removed and the
tubes were left open at room temperature for two minutes to
allow the remaining ethanol to evaporate. The pellets were
dissolved in 10 μΐ aqua ad iniectabilia and used directly or
stored frozen at -20 °C (modified ace. to I.e. (18)).
Ul t racent r i fugat ion
Concentration of samples: 3.5 ml serum were diluted with 31.5
ml of autoclaved 0.2 mol/1 phosphate buffered saline, pH 7.5,
and centrifuged for 3 hours at 100 000 g, 4 °C (Kontron T-2070
centrifuge, TFT 7038 rotor, 35000 min"1). The pellet was
dissolved in 650 μΐ guanidinium isothiocyanate solution and
immediately processed as described above.
Simulated concentration from pooled samples: three 200 μΐ
serum samples known to contain hepatitis C virus were mixed
each with 3.8 ml serum from healthy blood donors and 31 ml
phosphate-buffered saline. A 200 μΐ sample was taken from
each of these dilutions. After centrifugation, 200 μΐ samples
drawn from the upper and the lower zone of the supernatants,
and the pellets were all extracted with guanidinium salt solution
as described above. The RNA extracts were dissolved in 10 μΐ
aqua ad iniectabilia. Samples (2 μΐ) of the RNA extracts were
used to make dilution series (10°, ΙΟ1, ΙΟ2, 103, 104-fold). All
dilution RNA solutions were subjected to reverse transcription
with Moloney murine leukaemia virus reverse transcriptase and
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Reverse transcription
RNA extract (2 μΐ) was used for reverse transcription with 20
units of Moloney murine leukaemia virus reverse transcriptase
(Pharmacia, Freiburg) and 20 units of RNAse inhibitor from
human placenta (RNA Guard, pharmacia), in 20 μΐ reactions
containing 5mmol/l HEPES, 50 mmol/1 Tris-Cl pH 7.5, 73
mmol/1 KC1, 3 mmol/1 MgCl2,10 mmol/11,4-dithiothreitol, and
0.5 mmol/1 of each 2'-deoxynucleoside triphosphate. The con-
centration of the downstream primer (either NCR 2 or ED 2)
was 1 μιηοΐ/ΐ. The reaction mixtures were overlaid with a drop
of liquid paraffin (DAB 9) and left at 37 °C for 90 minutes,
then heated to 95 °C for 5 minutes and chilled on ice for 2
minutes before further processing or storage at — 20 °C.
Alternatively, recombinant reverse transcriptase from Thermus
aquaticus ("thermostable reverse transcriptase", Perkin Elmer
Cetus), an enzyme with both reverse transcriptase and DNA
polymerase activities, was used for reverse transcription and
the subsequent polymerase chain reaction according to the
manufacturer's protocol: 2 μΐ aqueous solution of extracted
RNA were made up to a total volume fo 20 μΐ, containing 1.0
mmol/1 MnCl2, 10 mmol/1 Tris-Cl pH 8.3, 90 mmol/1 KC1, 200
μτηοΐβ of each 2/-deoxynucleoside triphosphate, 0.75 μηιοΐ/ΐ
downstream primer (NCR 2 or ED 2) and 5 units of thermost-
able reverse transcriptase. The mixtures were overlaid with
paraffin and incubated at 70 °C for 10 minutes. Then the total
volume was increased to 100 μΐ by addition of 8 μΐ "chelating
buffer" (containing glycerol, volume fraction 0.5, 100 mmol/1
Tris-Cl pH 8.3, 1 mol/1 KC1, 7.5 mmol/1 EGTA and 5,0 g/1
Tween 20), 10 μΐ 25 mmol/1 MgCl2, 1 μΐ 20 μηιοΙ/1 upstream
primer (NCR 1 or ED 1), and 61 μΐ water, and the polymerase
chain reaction was started.
Oligonucleotide primers
Syntheses were performed using phosphite technology on an
automated synthesizer (Applied Biosystems, Pfungstadt). After
cleavage of the protecting groups, the oligonucleotides were
purified by gel electrophoresis on 18% polyacrylamide gels (34).
Properties of the oligonucleotides are listed in table 1.
Polymerase chain reaction
A 5 μΐ fraction of a completed Moloney murine leukaemia virus
reverse transcriptase reaction mixture was transferred to a 0.75
ml thermocycler tube, using stuffed pipette tips to prevent
carryover via aerosols. The total polymerase chain reaction mix
was 50 μΐ, containing 50 mmol/1 KC1, 20 mmol/1 Tris-Cl pH
8.4, 1.5 mmol/1 MgCl2, 0.1 g/1 gelatin, 200 μηιοΐ/ΐ of each 2'-
deoxynucleoside-5'-triphosphate, 0.4 μηιοΐ/l of both oligonu-
cleotide primers and 2 units of Thermus aquaticus DNA poly-
merase (Perkin Elmer). When a single set of primers was used,
35 thermal cycles were performed. For the "nested" polymerase
chain reaction, 35 cycles were performed, and an aliquot of the
reaction mix was then transferred to new tubes for further
amplification in another 30 thermal cycles. In order to prevent
"amplificate carryover", we followed the guidelines given by
Kwok (35). The work was divided into three activities: Pre
amplification, amplification, and post amplification; a separate
room was reserved for each.
In order to exclude false positive results, parallel polymerase
chain reactions were performed using cDNA and untranscribed
RNA extracts. For negative controls we used the complete
polymerase chain reaction mixes run in the same series of
amplifications, but without cDNA; for positive controls we
used cDNA samples obtained by reverse transcription of guan-
idinium salt RNA extracts of the serum of a viraemic hepatitis
C patient.
Nested polymerase chain reaction
The incubation mixture of the first amplification reaction (1 μΐ)
was transferred with a disposable glass capillary pipette (Siid-
Laborbedarf, Gauting) into a thermocycler tube containing
24 μΐ polymerase chain reaction mix as described for the first
amplification, but with "nested" primers NCR 3 and NCR 4
instead of "outer" primers NCR 1 and NCR 2, or with J 1 and
J 2 instead of ED 1 and ED 2. 30 thermal cycles were per-
formed.
Temperature cycle conditions
1 minute 94 °C, 1 minute annealing temperature (see tab. 1), 1
minute 72 °C. In order to reduce the time intervals required for
temperature adjustment, a thermocycler equipped with high
capacity Peltier elements was used (Landgraf, Hannover). Typ-
ical heating and cooling rates were 2.7 — 2.9 °C/s, permitting
completion of 30 temperature cycles in 115 minutes.
Monitoring of amplificate carryover
Swab controls of all places involved in work with polymerase
chain reaction were taken every two weeks by excessive scratch-
ing of the control area with plastic pipettes. The pipette tips
were then cut off with single-use razor blades, placed in ther-
mocycler tubes containing reaction mix for the polymerase
chain reaction, and the nested polymerase chain reaction was
performed with nested primers NCR 1 —NCR 4. Possible aer-
osol transfer of amplificates was monitored by placing open
tubes on ice, containing a complete reaction mix for the poly-
merase chain reaction, for periods of up to four hours in many
parts of the laboratory, and subsequent performance of the
polymerase chain reaction. RNA extracts were subjected to the
polymerase chain reaction in parallel with the samples which
had been reverse transcribed into cDNA.
Amplificate analysis
Samples (8 μΐ), either from a 25 μΐ "nested" polymerase chain
reaction, from a 100 μΐ polymerase chain reaction with ther-
mostable reverse transcriptase, or from a 50 μΐ polymerase chain
reaction with a single set of primers, were mixed with 3 μΐ 300
g/1 sucrose, 1 g/1 bromphenol blue, 1 g/1 xylene cyanol in 450
mmol/1 Tris borate, pH 8.3, 10 mmol/1 EDTA, loaded onto
agarose gels (3 g/1 agarose, 3 :1 NuSieve, FMC BioProducts)
and run for 1 hour at 5 V/cm in Tris/borate/EDTA buffer (90
mmol/1 Tris borate, pH 8.3, 2 mmol/1 EDTA) in parallel with
molecular mass markers (Boehringer DNA markers V with
8-587 nucleotides and VIII with 19-1114 nucleotides). The
gels were stained at room temperature for 45 minutes in Tris/
borate/EDTA buffer containing 1 mg/1 ethidium bromide and
photographed on a 312 nm transilluminator (8000 μW/cm2,
Renner, Pfungstadt) under a fume hood.
Sequence determination of amplificates
Slices containing ethidium bromide-stained amplificates were
excised from agarose electrophoresis gels, and the amplificates
were purified by absorption to silica with "spin bind" sintered
glass centrifuge columns (FMC Bioproducts, distributed by
Biozym, Hameln) according to the manufacturer's protocol.
The purified material was blunt-end ligated into M 13 plasmids,
cloned, and sequenced according to I.e. (36), using 2'-deoxy-
cytidine a-[35S]thiophosphate as a label.
Anti-hepatitis C virus antibody detection
Anti-hepatitis C virus antibody screening was performed with
a "2nd generation" enzyme immunoassay employing a combi-
nation of recombinant hepatitis C virus peptides (Abbott, Wies-
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baden) (11). Positive test results were confirmed by parallel
testing with two supplementary enzyme immunoassays employ-
ing structural and non-structural hepatitis C virus antigens,
respectively (Abbott, Wiesbaden). When both supplementary
assays were negative, the and hepatitis C virus antibody status
was defined as negative, and the positive reaction in the screen-
ing assay was assumed to be false positive.
Determina t ion of serum alanine aminot ransferase
activi ty
The optimized standard method of the German Society of
Clinical Chemistry was used (37).
Results
Comparison of different primer pairs (tab. 2)
Thirty six anti hepatitis C virus antibody positive sera
(22 from hepatitis C patients, 14 from blood donors)
were extracted by the guanidinium salt method, and
RNA was reverse transcribed with Moloney murine
leukaemia virus reverse transcriptase. Hepatitis C vi-
rus RNA was detected in 21 of these sera (all from
hepatitis C patients). Nested polymerase chain reac-
tion with primers NCR 1 —NCR 4 detected hepatitis
C virus RNA in all of these 21 sera, the primer pair
NCR I/NCR 2 alone detected RNA in 19 of the sera,
the primer pair ED 1/ED2 in 16 sera, and nested
polymerase chain reaction with ED I/ED 2 and J I/
J 2 in only 5 sera. The latter finding is due to the fact
that primers J 1/J 2 were originally designed for de-
tection of the Japanese strain of hepatitis C virus, not
the European/American strains. They do not perfectly
match the amplificate obtained with the primer pair
EDI/ED 2.
Efficiency of different RNA extraction
methods (tab. 3)
Twenty two anti-hepatitis C virus antibody positive
sera (13 from blood donors, 9 from hepatitis C pa-
tients) were extracted using three different methods
(guanidinium salt, proteinase K, and polyethylene
glycol precipitation). Ultracentrifugation prior to
RNA extraction was performed in parallel.
Tab. 2. Comparison of different pairs of oligonucleotide primers.
Sequences of the oligonucleotide primers and their relative positions in the hepatitis C virus genome are listed in table 1.
+: amplificate of expected size detected by ethidium fluorescence after polymerase chain reaction.
— : no amplificate detected
Oligonucleotide primers: NCR 1 —NCR 4 from the 5'-terminal non-coding region, ED I/ED 2 and J 1/J 2 from the coding
region of the hepatitis C virus genome.
Samples 1—22 were from anti-hepatitis C virus antibody positive hepatitis C patients, samples 23 — 36 were from anti-
hepatitis C virus antibody-positive blood donors.
























NCR I/NCR 2 NCR I/NCR 2 ED I/ED 2 ED I/ED 2
(35 cycles) (35 cycles) (35 cycles) (35 cycles)
and nested and nested
NCR 3/NCR 4 J 1/J 2
(30 cycles) (30 cycles)
+ + 4- +
4- 4 - 4 - 4 -
4- 4 - 4 - 4 -
+ 4- 4- —
4- 4- 4- —
4- 4- 4- —
4- 4- 4- —
4- + + —
+ + 4- —
4- + + —
+ H- 4- —
+ 4- + —
+ + H- —
-l_ 4- .]_ _
4- 4- H- —
4- + — —
_j_ 4. _ _
4- 4- — —
+ + — —
— 4 - 4 - 4 -
4-
all- all- all- all -
19 positive 21 positive 16 positive 5 positive
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Seventeen anti-hepatitis C virus antibody-positive
sera from haemophiliacs were extracted both with
guanidinium salt and proteinase K/phenol. Extraction
with guanidinium salt solution gave the best overall
yield. Polyethylene glycol precipitation performed
poorly.
Ultracentrifugation of large serum samples did not
improve the overall performance of RNA extraction.
The same pattern of positive and negative polymerase
chain reaction results was obtained after direct ex-
traction of 200 μΐ serum and after prior concentration
of the virus particles from 3.5 ml serum by ultracen-
trifugation.
When the overnight alcohol precipitation step of
RNA was shortened, the resulting material was of
poor quality, resulting in co-amplification of many
artefacts along with the desired amplificates. As
judged from the amplificate electrophoresis patterns,
the parallel extraction with one method of serum,
citrate plasma and EDTA plasma from the same
patient led to identical results (8 patients tested).
Three frozen sera from viraemic patients with chronic
hepatitis C, which served as positive controls, were
thawed on ten occasions in order to remove small
samples for RNA extraction. Hepatitis C virus RNA
was consistently detected in these samples by the
combination: guanidinium salt extraction/reverse
transcription/ nested polymerase chain reaction with
primers NCR 1- NCR 4.
Reverse transcription with two different en-
zymes (tab. 4)
Sixteen anti-hepatitis C virus antibody-positive sera
(7 from blood donors and 9 from hepatitis C patients)
were extracted with guanidinium salt solution, then
reverse transcribed in parallel with Moloney murine
leukaemia virus reverse transcriptase and with recom-
binant thermostable reverse transcriptase derived
from Thermus aquaticus (Perkin Elmer). Among the
7 blood donor sera used in this investigation, we
included deliberately 4 sera in which hepatitis C virus
RNA had previously been detected, so that the effi-
ciency of the reverse transcriptases would be tested
with sera of low viraemia. From 13 sera, including
the 4 blood donor sera, cDNA was obtained with
Moloney murine leukaemia virus reverse transcrip-
tase, whereas recombinant thermostable reverse tran-
scriptase yielded cDNA from only 7 patient sera and
from no blood donor sera. cDNA was amplified by
nested polymerase chain reaction with primers
NCR 1- NCR 4.
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Tab. 4. Comparison of two reverse transcriptases
Sixteen anti-hepatitis C virus antibody positive sera were used. Nested polymerase chain reaction with cDNA was
performed with oligonucleotide primers NCR 1 —NCR 4; assays with cDNA from thermostable reverse transcriptase were
performed in duplicate.
-I-: Amplificate detected with ethidium bromide stain.
— : No amplificate detected.
Guanidinium extract: Sera extracted with guanidinium salt/detergent
Proteinase K extract: Sera extracted with proteinase K/phenol





Blood donors (n = 7)
(Guanidinium extract)
Hepatitis C patients (n = 9)
(Guanidinium extract)
(Proteinase K extract)






Proportion of viraemic anti-hepatitis C virus
antibody positive individuals in different
groups (tabs. 5 and 6)
Anti-hepatitis C virus antibody-positive sera from
apparently healthy blood donors, from patients with
hepatopathies and from haemophiliacs who had re-
Tab. 5. Proportion of hepatitis C virus carriers in different
groups of anti-hepatitis C virus antibody positive in-
dividuals.
RNA was extracted with guanidinium salt solution;
cDNA was made with Moloney murine leukaemia virus
reverse transcriptase and amplified with nested primers
















ceived multiple doses of human plasma products be-
fore the introduction of virus inactivation procedures,
were assayed by the polymerase chain reaction, fol-
lowing RNA extraction with guanidinium salt solu-
tion and reverse transcription with Moloney murine
leukaemia virus reverse transcriptase. Hepatitis C vi-
rus RNA was detected in 90% of the haemophiliacs
(17 of 19), and in 90% of the patients with clinically
manifest "hepatitis non-A, non-B" (27 of 30), but
only in 11 % of apparently healthy blood donors with
anti-hepatitis C virus antibodies and normal serum
alanine aminotransferase (4 of 36).
Examination of sera with elevated alanine
aminotransferase catalytic concentrations
Four hundred and fifty anti-hepatitis C virus anti-
body-negative sera from blood donors with elevated
serum alanine aminotransferase (> 25 U/l) were ex-
tracted with guanidinium salt solution. The RNA
extracts were reverse transcribed with Moloney mu-
Tab. 6. Detection of hepatitis C virus RNA in sera from haemophiliacs.
Antibodies were detected with 2nd generation enzyme anti-hepatitis C immunoassay (Abbott, Wiesbaden). cDNA was
prepared with Moloney murine leukaemia virus reverse transcriptase and amplified with nested primers NCR 1 —NCR 4.
Number of
patients
Clotting factor therapy Anti-hepatitis C
serostatus
Hepatitis C virus
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rine leukaemia virus reverse transcriptase, and nested
polymerase chain reaction was performed with oli-
gonucleotide primers NCR 1—NCR 4. No amplifi-
cates were observed.
Ultracentrifugation of viraemic samples
Virtually all virus particles were sedimented from very
diluted serum samples by Ultracentrifugation. RNA
was extracted from three 200 μΐ serum samples and
in parallel from the pellets obtained after Ultracentri-
fugation of such 200 μΐ samples diluted in 35 ml
phosphate buffered saline solution. Both types of
RNA extracts had the same virus RNA titre (detec-
tion limit 103-fold dilution), indicating that all the
RNA contained in a 200 μΐ serum sample could be
recovered after ca. 160-fold dilution and subsequent
Ultracentrifugation.
Sequence determination of amplificates
Four amplificates from nested polymerase chain re-
action with primers NCR 1-NCR 4 from the 5'-
terminal non-coding region, spanning the sequence
from nucleotide 10 to 288, were sequenced. Nucleotide
exchanges, as compared with the hepatitis C virus 5'-
terminal nucleotide sequence as published by Oka-
moto (21), occurred at three positions (tab. 7).
Tab. 7. Nucleotide sequence deviations of hepatitis C virus
cDNA amplificates from the 5'-terminal sequence as
published by Okamoto (21)







187 A to T,
187 A to C,
187 A to T,
217 C to T,
217 C to T,
217 C to T,
217 C to T,
287 A to G
287 A to G
Discussion
The combination of RNA extraction, reverse tran-
scription and subsequent polymerase chain reaction
is presently the only sensitive method available for
hepatitis C virus detection that permits the prediction
of infectivity of patients and blood donors. We were
able to demonstrate that stepwise optimization of this
method can eliminate many false negative results.
Guanidinium salt solution was superior to other RNA
extraction methods. Reverse transcription and sub-
sequent cDNA amplification with nested oligonucleo-
tide primers targeted to the S'-terminal non-coding
region of the hepatitis C virus genome detected the
virus more often than with other primers (21, 22) (tab.
2). These results suggest that some recently published
data on the prevalence of hepatitis C virus in anti-
hepatitis C virus antibody positive patients and hae-
mophiliacs may harbour some false negatives, since
they were obtained using sub-optimal RNA extraction
methods and primers (12, 16, 20). In order to accu-
mulate comparable data from different laboratories
about hepatitis C virus prevalence in large numbers
of samples, evaluation and standardization of the
RNA detection procedures is required, including
especially RNA extraction, reverse transcription, se-
lection of oligonucleotide primers, and thermocycle
conditions.
Hepatitis C virus particles may be recovered even
from very dilute solutions by Ultracentrifugation. Al-
though this concentration step is not required when
hepatitis C virus RNA is to be detected in single
serum samples, Ultracentrifugation may be very useful
in the screening of large numbers of serum samples
for hepatitis C virus. All virus particles contributed
to a serum pool by a single serum sample will be
recovered from the pellet after Ultracentrifugation, in
spite of the dilution effect caused by the pooling. This
approach is especially efficient when only very few of
the screened samples contain the hepatitis C virus, as
should be the case with preselected anti-hepatitis C
virus antibody-negative blood donors. Such a screen-
ing can close the diagnostic window between hepatitis
C virus infection and anti-hepatitis C seroconversion.
Hepatitis C virus detection in all blood donations,
combined with antibody screening, should be made
mandatory with the aim of preventing transfusion-
related hepatitis C virus transmissions.
We found markedly different proportions of virus
carriers in three groups of anti-hepatitis C virus an-
tibody positive people, namely hepatitis C patients,
haemophiliacs and blood donors (tab. 5).
The rate of 90% hepatitis C virus carriers among
"hepatitis non-A, non-B" patients both with acute
and chronic disease reflects the strong tendency of the
hepatitis C infection to become chronic. With this in
mind, we should undertake every possible effort to
prevent the iatrogenic transmission of this virus in-
fection, e. g. via blood transfusions.
We examined sera from 19 haemophiliacs who had
received multiple doses of human plasma products
before the introduction of virus inactivation proce-
dures. All of them had anti-hepatitis C virus antibod-
ies, and 17 of them carried the hepatitis C virus.
Plasma derived clotting factor is the most likely source
of their hepatitis C infections (38, 39). Another 3
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haemophiliacs in our study had been treated exclu-
sively with virus-inactivated plasma products. They
had no anti-hepatitis C virus antibodies and were not
viraemic (tabs. 5 and 6). These findings reflect both
the usefulness of virus inactivation procedures and
the fact that viraemic plasma donors have contributed
and probably continue to contribute to human plasma
pools.
Among 36 anti-hepatitis C virus antibody positive
blood donors, we found only 11% (4 of 36) viraemic
individuals (tab. 5). This observation suggests that
their apparent well-being correlated with periods of
aviraemia. However, these blood donors were prese-
lected, because we require that our blood donors be
anti-HBc negative.
Anti-HBc antibodies are regarded as a marker not
only for hepatitis B, but rather as marker of increased
susceptibility to other infections which may be trans-
mitted by blood. There are reports in the literature
of the detection of anti-hepatitis C virus antibodies
in archivated sera from blood donors involved in
transfusion-related "heaptitis non-A, non-B" trans-
mission (40 — 42). These donors had not been pre-
screened for anti-HBc antibodies and must be re-
garded as chronic hepatitis C virus carriers from their
history. Two other reports (43, 44) give data about
anti-hepatitis C virus antibody status and hepatitis C
virus detection in the sera of randomly selected blood
donors in London and in Australia who had not been
prescreened for anti-HBc antibodies. The proportion
of hepatitis C virus carriers among the anti-hepatitis
C virus antibody positive blood donors in these stud-
ies was higher than in our study. In a study on blood
donors with elevated serum alanine aminotransferase
(13), ca. 8% of the donors were found to be hepatitis
C virus carriers and 4% were anti-HBc antibody-
positive. Anti-HBc screening prior to the admission
of blood donors obviously helps to identify some
hepatitis C virus carriers.
Elevated serum alanine aminotransferase in donated
blood has previously served as a surrogate marker to
hepatitis non-A, non-B in Germany. Even after intro-
duction of the anti-hepatitis C virus antibody screen-
ing, serum alanine aminotransferase determination
was continued in order to detect hepatitis C virus
infections during the interval before seroconversion.
We did not detect hepatitis C virus RNA in 450 blood
donor sera with elevated alanine aminotransferase
(above 25 U/l). Moreover, all the viraemic blood
donors in our study did not have elevated serum
alanine aminotransferase, nor had they ever had ele-
vated serum alanine aminotransferase during their
history as blood donors. If serum alanine aminotrans-
ferase activity in blood donors cannot detect hepatitis
C infections, what is its purpose now?
The usefulness of the polymerase chain reaction, com-
bined with efficient nucleic acid extraction, for the
detection of hepatitis C virus has been demonstrated.
The method can be adapted to screening procedures
and will soon find many routine applications both in
transfusion medicine and in general infectiology.
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